Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Biotechnology

Editor-in-Chief

ISSN (Print): 1389-2010
ISSN (Online): 1873-4316

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Systematic Review Article

The Possible Protective Effect of Hepatitis B Vaccine against Lymphomas: A Systematic Review

Author(s): Lorenza Lia, Daniela Grima, Francesca Amici, Linda Manzi, Alessandro Monaci and Giuseppe La Torre*

Volume 23, Issue 15, 2022

Published on: 13 May, 2022

Page: [1864 - 1872] Pages: 9

DOI: 10.2174/1389201023666220113111946

Price: $65

Abstract

Background: In the last few years, the possible etiological role of the Hepatitis B virus (HBV) in the outbreak of extrahepatic pathologies has been studied, including lymphomas. The World Health Organization (WHO) estimates that around 257 million people live with chronic HBV infection, and to date, the vaccine is the most effective means of prevention.

Objective: The aim of this review was to evaluate whether the vaccination against Hepatitis B can lead to a reduction in lymphoma cases and has a protective role.

Methods: A literature search was conducted in April 2020 using the databases Scopus, PubMed, and ISI Web of Science. Search terms included: “Hepatitis B vaccination AND lymphoma.” All articles evaluating the association between Hepatitis B vaccination and the prevention of lymphoma were selected. No limits were applied.

Results: Eight studies were eligible to be included in the review. Data showed that association between lymphoma and HBV infection is not the same for all types of lymphomas, but it appears to be more significant for Non-Hodgkin Lymphoma (NHL). The results from all the considered articles were not unitary. This is because studies were conducted in different countries with different endemicity of Hepatitis B, different vaccination coverage, treatment of chronic Hepatitis, and prevention of its complications, as well as the availability of data for researchers. No statistically significant association was found between HBV vaccination and the development of lymphomas.

Conclusion: Although the literature is still largely lacking regarding the protective effect of anti- HBV vaccination on lymphoma subtypes, the association between HBV infection and lymphoma has been confirmed in several studies. Vaccination programs eliminate the risk of HBV infection and prevent liver disease but can also indirectly reduce the risk of lymphomas.

Keywords: Hepatitis B, vaccination, lymphoma, prevention, anti-HBV vaccination, blood.

« Previous Next »
Graphical Abstract

[1]
Epicentro. L’epidemiologia per la Sanità Pubblcia by The Italian National Institute of Health. Viral Hepatitis, Hepatitis B. Available from: https://www.epicentro.iss.it/epatite/epatite-b (accessed on 20 April 2020).
[2]
Centers for Disease Control and Prevention (CDC). Viral Hepatitis, Hepatitis B. Available from: https://www.cdc.gov/Hepatitis/ hbv/index.htm (accessed on 20 April 2020).
[3]
World Health Organization (WHO). Hepatitis B. 2019. Available from: https://www.who.int/news-room/fact-sheets/detail/Hepatitis-b (accessed on 20 April 2020).
[4]
Stasi, C.; Silvestri, C.; Berni, R.; Brunetto, M.R.; Zignego, A.L.; Orsini, C.; Milani, S.; Ricciardi, L.; De Luca, A.; Blanc, P.; Nencioni, C.; Aquilini, D.; Bartoloni, A.; Bresci, G.; Marchi, S.; Filipponi, F.; Colombatto, P.; Forte, P.; Galli, A.; Luchi, S.; Chigiotti, S.; Nerli, A.; Corti, G.; Sacco, R.; Carrai, P.; Ricchiuti, A.; Giusti, M.; Almi, P.; Cozzi, A.; Carloppi, S.; Laffi, G.; Voller, F.; Cipriani, F. Clinical epidemiology of chronic viral hepatitis B: A Tuscany real-word large-scale cohort study. World J. Hepatol., 2018, 10(5), 409-416.
[http://dx.doi.org/10.4254/wjh.v10.i5.409] [PMID: 29844854]
[5]
Ott, J.J.; Stevens, G.A.; Groeger, J.; Wiersma, S.T. Global epidemiology of Hepatitis B virus infection: New estimates of agespecific HBsAg seroprevalence and endemicity. Elsevier, 2012, 30, 2212-2219.
[6]
Lim, S.T.; Fei, G.; Quek, R.; Lim, L.C.; Lee, L.H.; Yap, S.P.; Loong, S.; Tao, M. The relationship of hepatitis B virus infection and non-Hodgkin’s lymphoma and its impact on clinical characteristics and prognosis. Eur. J. Haematol., 2007, 79(2), 132-137.
[http://dx.doi.org/10.1111/j.1600-0609.2007.00878.x] [PMID: 17635237]
[7]
Engels, E.A.; Cho, E.R.; Jee, S.H. Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: A cohort study. Lancet Oncol., 2010, 11(9), 827-834.
[http://dx.doi.org/10.1016/S1470-2045(10)70167-4] [PMID: 20688564]
[8]
Kim, J.H.; Bang, Y.J.; Park, B.J.; Yoo, T.; Kim, C.W.; Kim, T.Y.; Heo, D.S.; Lee, H.S.; Kim, N.K. Hepatitis B virus infection and B-cell non-Hodgkin’s lymphoma in a hepatitis B endemic area: A case-control study. Jpn. J. Cancer Res., 2002, 93(5), 471-477.
[http://dx.doi.org/10.1111/j.1349-7006.2002.tb01280.x] [PMID: 12036441]
[9]
Mehdi, S.R.; Al Ajlan, A.R. Hepatitis, B. Hepatitis B& C virus infection in cases of Non-Hodgkin’s lymphoma in Saudi Arabia. Turk. J. Haematol., 2006, 23(4), 200-204.
[PMID: 27265663]
[10]
Zhou, X.; Pan, H.; Yang, P.; Ye, P.; Cao, H.; Zhou, H. Both chronic HBV infection and naturally acquired HBV immunity confer increased risks of B-cell non-Hodgkin lymphoma. BMC Cancer, 2019, 19(1), 477.
[http://dx.doi.org/10.1186/s12885-019-5718-x]
[11]
Dalia, S.; Chavez, J.; Castillo, J.J.; Sokol, L. Hepatitis B infection increases the risk of non-Hodgkin lymphoma: A meta-analysis of observational studies. Leuk. Res., 2013, 37(9), 1107-1115.
[http://dx.doi.org/10.1016/j.leukres.2013.06.007] [PMID: 23809055]
[12]
Fisher, S.G.; Fisher, R.I. The epidemiology of non-Hodgkin’s lymphoma. Oncogene, 2004, 23(38), 6524-6534.
[http://dx.doi.org/10.1038/sj.onc.1207843] [PMID: 15322522]
[13]
Dalia, S.; Suleiman, Y.; Croy, D.W.; Sokol, L. Association of lymphomagenesis and the reactivation of hepatitis B virus in non-hodgkin lymphoma. Cancer Contr., 2015, 22(3), 360-365.
[http://dx.doi.org/10.1177/107327481502200315] [PMID: 26351893]
[14]
Jaffe, E.S. Diagnosis and classification of lymphoma: Impact of technical advances. Semin. Hematol., 2019, 56(1), 30-36.
[http://dx.doi.org/10.1053/j.seminhematol.2018.05.007] [PMID: 30573042]
[15]
Dal Maso, L.; Franceschi, S. Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: A meta-analysis of epidemiologic studies. Cancer Epidemiol. Biomarkers Prev., 2006, 15(11), 2078-2085.
[http://dx.doi.org/10.1158/1055-9965.EPI-06-0308] [PMID: 17119031]
[16]
Pozzato, G.; Mazzaro, C.; Dal Maso, L.; Mauro, E.; Zorat, F.; Moratelli, G.; Bulian, P.; Serraino, D.; Gattei, V. Hepatitis C virus and non-Hodgkin’s lymphomas: Meta-analysis of epidemiology data and therapy options. World J. Hepatol., 2016, 8(2), 107-116.
[http://dx.doi.org/10.4254/wjh.v8.i2.107] [PMID: 26807206]
[17]
Miranda-Filho, A.; Piñeros, M.; Znaor, A.; Marcos-Gragera, R.; Steliarova-Foucher, E.; Bray, F. Global patterns and trends in the incidence of non-Hodgkin lymphoma. Cancer Causes Control, 2019, 30(5), 489-499.
[http://dx.doi.org/10.1007/s10552-019-01155-5] [PMID: 30895415]
[18]
Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med., 2009, 6(7), e1000097.
[http://dx.doi.org/10.1371/journal.pmed.1000097] [PMID: 19621072]
[19]
Wells, G.A.; Shea, B.; O’Connel, D.; Peterson, J.; Welch, V.; Losos, M.; Tugwell, P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2011.
[20]
La Torre, G.; Backhaus, I.; Mannocci, A. Rating for narrative reviews: Concept and development of the International Narrative Systematic Assessment tool. Senses Sci., 2015, 2, 31-35.
[21]
Schiller, J.T.; Lowy, D.R. Virus infection and human cancer: An overview. Recent Results Cancer Res., 2014, 193, 1-10.
[http://dx.doi.org/10.1007/978-3-642-38965-8_1] [PMID: 24008290]
[22]
Chen, C.J.; Hsu, W.L.; Yang, H.I.; Lee, M.H.; Chen, H.C.; Chien, Y.C.; You, S.L. Epidemiology of virus infection and human cancer. Recherches sur le Cancer, 2014, 1, 11-32.
[23]
Tashiro, H.; Brenner, M.K. Immunotherapy against cancer-related viruses. Cell Res., 2017, 27(1), 59-73.
[http://dx.doi.org/10.1038/cr.2016.153] [PMID: 28008927]
[24]
Hoppe-Seyler, F.; Hoppe-Seyler, K. Emerging topics in human tumor virology. Int. J. Cancer, 2011, 129(6), 1289-1299.
[http://dx.doi.org/10.1002/ijc.26087] [PMID: 21445966]
[25]
Vousden, K.H.; Farrell, P.J. Viruses and human cancer. Br. Med. Bull., 1994, 50(3), 560-581.
[http://dx.doi.org/10.1093/oxfordjournals.bmb.a072910] [PMID: 7987641]
[26]
Herrington, C.S.; Coates, P.J.; Duprex, W.P. Viruses and disease: Emerging concepts for prevention, diagnosis and treatment. J. Pathol., 2015, 235(2), 149-152.
[http://dx.doi.org/10.1002/path.4476] [PMID: 25366544]
[27]
Delgado-Enciso, I.; Rojas-Martínez, A.; Barrera-Saldaña, H.A.; Ortiz-López, R. Viruses: An important cause of human cancer. Rev. Invest. Clin., 2004, 56(4), 495-506.
[PMID: 15587296]
[28]
Rickinson, A.B. Immune intervention against virus-associated human cancers. Ann. Oncol., 1995, 6(Suppl. 1), 69-71.
[http://dx.doi.org/10.1093/annonc/6.suppl_1.S69] [PMID: 8695548]
[29]
Khayr, W.; Haddad, R.Y.; Noor, S.A. Infections in hematological malignancies. Dis. Mon., 2012, 58(4), 239-249.
[http://dx.doi.org/10.1016/j.disamonth.2012.01.001] [PMID: 22449371]
[30]
Kadow, J.F.; Regueiro-Ren, A.; Weinheimer, S.P. The role of viruses in human cancer development and antiviral approaches for intervention. Curr. Opin. Investig. Drugs, 2002, 3(11), 1574-1579.
[PMID: 12476955]
[31]
Koltan, S.; Koltan, A.; Wysocki, M.; Debski, R.; Styczynski, J. Anti-HBs profiles in children treated for neoplastic disease who had been vaccinated against hepatitis B postnatally or as infants. J. Hosp. Infect., 2005, 60(1), 73-77.
[http://dx.doi.org/10.1016/j.jhin.2004.09.041] [PMID: 15823661]
[32]
Paul, S.; Dickstein, A.; Saxena, A.; Terrin, N.; Viveiros, K.; Balk, E.M.; Wong, J.B. Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: A meta-analysis. Hepatology, 2017, 66(2), 379-388.
[http://dx.doi.org/10.1002/hep.29082] [PMID: 28128861]
[33]
Entacher, U.; Jürgenssen, O.; Thun-Hohenstein, L.; Simbruner, G.; Khoss, A.; Wank, H.; Neuwirth, G.; Gadner, H.; Frisch-Niggemeyer, W. Hepatitis B vaccination and immune response in children with malignant diseases. Eur. J. Pediatr., 1985, 144(2), 160-163.
[http://dx.doi.org/10.1007/BF00451904] [PMID: 4043127]
[34]
Goyal, S.; Pai, S.K.; Kelkar, R.; Advani, S.H. Hepatitis B vaccination in acute lymphoblastic leukemia. Leuk. Res., 1998, 22(2), 193-195.
[http://dx.doi.org/10.1016/S0145-2126(97)00155-0] [PMID: 9593476]
[35]
Lindemann, M.; Koldehoff, M.; Fiedler, M.; Schumann, A.; Ottinger, H.D.; Heinemann, F.M.; Roggendorf, M.; Horn, P.A.; Beelen, D.W. Control of hepatitis B virus infection in hematopoietic stem cell recipients after receiving grafts from vaccinated donors. Bone Marrow Transplant., 2016, 51(3), 428-431.
[http://dx.doi.org/10.1038/bmt.2015.253] [PMID: 26501767]
[36]
Lin, C.L.; Kao, J.H. Perspectives and control of hepatitis B virus infection in Taiwan. J. Formos. Med. Assoc., 2015, 114(10), 901-909.
[http://dx.doi.org/10.1016/j.jfma.2015.06.003] [PMID: 26184565]
[37]
Ewald, P.W.; Swain Ewald, H.A. Joint infectious causation of human cancers. Adv. Parasitol., 2014, 84, 1-26.
[http://dx.doi.org/10.1016/B978-0-12-800099-1.00001-6] [PMID: 24480312]
[38]
Faivre, G.; Thibault, V.; Tanguy, M.L.; Leblond, V.; Choquet, S.; Soussain, C.; Gonzalez-Aguilar, A.; Sierra del Rio, M.; Houillier, C.; Hoang-Xuan, K.; Idbaih, A. Prevalence of hepatitis B virus in primary central nervous system lymphoma. J. Neurooncol., 2015, 125(1), 219-221.
[http://dx.doi.org/10.1007/s11060-015-1879-x] [PMID: 26272598]
[39]
Kleinstern, G.; Seir, R.A.; Perlman, R.; Abdeen, Z.; Khatib, A.; Elyan, H.; Dann, E.J.; Kedmi, M.; Ellis, M.; Nagler, A.; Amir, G.; Ben Yehuda, D.; Safadi, R.; Paltiel, O. Associations between B-cell non-Hodgkin lymphoma and exposure, persistence and immune response to hepatitis B. Haematologica, 2016, 101(7), e303-e305.
[http://dx.doi.org/10.3324/haematol.2016.144840] [PMID: 27102500]
[40]
Johnson, T.M. Treatment and management of chronic lymphocytic leukemia in the elderly: What the pharmacist clinician should know. Consult Pharm., 2012, 27(4), 274-285.
[http://dx.doi.org/10.4140/TCP.n.2012.274] [PMID: 22498987]
[41]
Becker, N.; Schnitzler, P.; Boffetta, P.; Brennan, P.; Foretova, L.; Maynadié, M.; Nieters, A.; Staines, A.; Benavente, Y.; Cocco, P.; de Sanjose, S. Hepatitis B virus infection and risk of lymphoma: Results of a serological analysis within the European case-control study Epilymph. J. Cancer Res. Clin. Oncol., 2012, 138(12), 1993-2001.
[http://dx.doi.org/10.1007/s00432-012-1279-y] [PMID: 22767316]
[42]
Fwu, C.W.; Chien, Y.C.; Nelson, K.E.; Kirk, G.D.; You, S.L.; Kuo, H.S.; Feinleib, M.; Chen, C.J. Mortality after chronic hepatitis B virus infection: A linkage study involving 2 million parous women from Taiwan. J. Infect. Dis., 2010, 201(7), 1016-1023.
[http://dx.doi.org/10.1086/651231] [PMID: 20187745]
[43]
Fwu, C.W.; Chien, Y.C.; You, S.L.; Nelson, K.E.; Kirk, G.D.; Kuo, H.S.; Feinleib, M.; Chen, C.J. Hepatitis B virus infection and risk of intrahepatic cholangiocarcinoma and non-Hodgkin lymphoma: A cohort study of parous women in Taiwan. Hepatology. 2011, 53, 1217-1225.lymphoma: A cohort study of parous women in Taiwan. Hepatology, 2011, 53(4), 1217-1225.
[http://dx.doi.org/10.1002/hep.24150] [PMID: 21480326]
[44]
Franceschi, S.; Lise, M.; Trépo, C.; Berthillon, P.; Chuang, S.C.; Nieters, A.; Travis, R.C.; Vermeulen, R.; Overvad, K.; Tjønneland, A.; Olsen, A.; Bergmann, M.M.; Boeing, H.; Kaaks, R.; Becker, N.; Trichopoulou, A.; Lagiou, P.; Bamia, C.; Palli, D.; Sieri, S.; Panico, S.; Tumino, R.; Sacerdote, C.; Bueno-de-Mesquita, B.; Peeters, P.H.; Rodríguez, L.; Barroso, L.L.; Dorronsoro, M.; Sánchez, M.J.; Navarro, C.; Barricarte, A.; Regnér, S.; Borgquist, S.; Melin, B.; Hallmans, G.; Khaw, K.T.; Wareham, N.; Rinaldi, S.; Hainaut, P.; Riboli, E.; Vineis, P. Infection with hepatitis B and C viruses and risk of lymphoid malignancies in the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Epidemiol. Biomarkers Prev., 2011, 20(1), 208-214.
[http://dx.doi.org/10.1158/1055-9965.EPI-10-0889] [PMID: 21098651]
[45]
Huang, C.E.; Yang, Y.H.; Chen, Y.Y.; Chang, J.J.; Chen, K.J.; Lu, C.H.; Lee, K.D.; Chen, P.C.; Chen, C.C. The impact of hepatitis B virus infection and vaccination on the development of non-Hodgkin lymphoma. J. Viral Hepat., 2017, 24(10), 885-894.
[http://dx.doi.org/10.1111/jvh.12713] [PMID: 28375587]
[46]
Marcucci, F.; Spada, E.; Mele, A.; Caserta, C.A.; Pulsoni, A. The association of hepatitis B virus infection with B-cell non-Hodgkin lymphoma - a review. Am. J. Blood Res., 2012, 2(1), 18-28.
[PMID: 22432084]
[47]
Taborelli, M.; Polesel, J.; Montella, M.; Libra, M.; Tedeschi, R.; Battiston, M.; Spina, M.; Di Raimondo, F.; Pinto, A.; Crispo, A.; Grimaldi, M.; Franceschi, S.; Dal Maso, L.; Serraino, D. Hepatitis B and C viruses and risk of non-Hodgkin lymphoma: A case-control study in Italy. Infect. Agent. Cancer, 2016, 11, 27.
[http://dx.doi.org/10.1186/s13027-016-0073-x] [PMID: 27340429]
[48]
Wang, C.; Xia, B.; Ning, Q.; Zhao, H.; Yang, H.; Zhao, Z.; Wang, X.; Wang, Y.; Yu, Y.; Zhang, Y. High prevalence of hepatitis B virus infection in patients with aggressive B cell non-Hodgkin’s lymphoma in China. Ann. Hematol., 2018, 97(3), 453-457.
[http://dx.doi.org/10.1007/s00277-017-3188-2] [PMID: 29188315]
[49]
European Data News Hub. Mandatory vaccinations in Europe., Available from: https://www.ednh.news/it/vaccini-ecco-la-mappadi-quelli-obbligatori-nellue/ (accessed on 28 April 2020).
[50]
World Health Organization (WHO). Global Hepatitis Report, 2017, 24-25. Available from: https://www.who.int/publications/i/item/global-hepatitis-report-2017 (accessed on 28 April 2020).
[51]
AIRC. Immunotherapies and vaccines., 2016. Available from: https://www.airc.it/cancro/affronta-la-malattia/guida-alle-terapie/immunoterapie-e-vaccini (accessed on 10 September 2020).
[52]
Zou, Z.Q.; Wang, L.; Wang, K.; Yu, J.G. Innate immune targets of hepatitis B virus infection. World J. Hepatol., 2016, 8(17), 716-725.
[http://dx.doi.org/10.4254/wjh.v8.i17.716] [PMID: 27330680]
[53]
Tulchinsky, TH creator of vaccines that changed the world. case studies in public health. 2018, 443-470.
[http://dx.doi.org/10.1016/B978-0-12-804571-8.00003-2]
[54]
Cooper, C.; Mackie, D. Hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine: A review of HEPLISAV™ safety and efficacy. Expert Rev. Vaccines, 2011, 10(4), 417-427.
[http://dx.doi.org/10.1586/erv.10.162] [PMID: 21506639]

Rights & Permissions Print Cite
Article Metrics
5
© 2024 Bentham Science Publishers | Privacy Policy